DDInter1609 DDInter1652
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Rivaroxaban {u} (Compound) resembles {v} (Compound) Linezolid
Rivaroxaban {u} (Compound) binds {v} (Gene) ABCB1
Rivaroxaban {u} (Compound) upregulates {v} (Gene) CDK6
Rivaroxaban {u} (Compound) downregulates {v} (Gene) GJA1
Rivaroxaban {u} (Compound) causes {v} (Side Effect) Pruritus
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Rivaroxaban {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Rivaroxaban (Compound) resembles Linezolid (Compound)
Rivaroxaban (Compound) binds ABCB1 (Gene)
Rivaroxaban (Compound) upregulates CDK6 (Gene)
Rivaroxaban (Compound) downregulates GJA1 (Gene)
Rivaroxaban (Compound) causes Pruritus (Side Effect)
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Rivaroxaban may lead to a major life threatening interaction when taken with Regorafenib